Stock Splits
By The Online Investor Staff, updated Mon., Feb. 6, 2:18 AM
| This Slide: #6 of 25 |
Slide #6. Phio Pharmaceuticals Corp. (NASDAQ:PHIO) — 1 for 12 Reverse Split
Announced:
1/25/2023
Stock Split:
1 for 12
Record Date:
1/25/2023
Pay Date:
1/26/2023
PHIO Optionable?:
Yes
Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT. 
PHIO Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the PHIO Page at The Online Investor (in a new window) »
 Free PHIO Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
